Intuitive Surgical stock gains on EU approval and strong Q2 growth

Intuitive Surgical stock (ISIN US46120E6023) is trading around USD 383 on Nasdaq as of September 16, 2026, supported by fresh regulatory approval in Europe and robust second-quarter 2026 growth figures. As Yahoo Finance reported on September 16, 2026, the company secured CE mark approval to expand the da Vinci SP system in gynecologic procedures, a catalyst that underpins the current share price and investor interest.

CE mark approval expands da Vinci SP platform

According to Yahoo Finance on September 16, 2026, Intuitive Surgical received CE mark approval for the da Vinci SP system in Europe for transvaginal gynecologic procedures, widening its labeled use for single port, natural orifice surgery across multiple disciplines. This decision broadens the system’s clinical reach beyond earlier indications and strengthens the company’s foothold in minimally invasive gynecologic surgery in the European market.

The approval comes on top of growing momentum for the da Vinci SP platform in the latest reported quarter. Per the same Yahoo Finance report, in the second quarter of 2026 Intuitive Surgical placed 38 da Vinci SP systems, up from 23 a year earlier, lifting the global installed base to 445 systems. SP procedures in that period surged 61 percent year over year, driven by strong adoption in the United States and Korea and encouraging early traction in Europe, Japan and Taiwan, highlighting how regulatory expansion can translate directly into higher usage.

Q2 2026 revenue and earnings show double-digit growth

The latest financial figures underline the strength of Intuitive Surgical’s business going into the new regulatory phase. An overview from Deep500 summarizing recent results notes that in Q2 2026 the company generated revenue of USD 2.89 billion, an increase of 18.5 percent year over year, while worldwide procedure volumes rose 16 percent and da Vinci system placements reached 468 units in the quarter. This combination of nearly 20 percent top-line growth and mid-teens procedure expansion indicates that demand for robotic-assisted surgery remains strong across regions.

Profitability also improved markedly. Data compiled by Smart-lab for Q2 2026 show operating income of USD 971.9 million, up 31 percent year over year, reflecting strong leverage on the growing revenue base. Over the last four quarters to Q2 2026, operating income reached about USD 3,223 million, confirming that margins have expanded consistently alongside volume growth.

Earnings per share moved in step with operating profit. The same Smart-lab overview lists Q2 2026 GAAP EPS at USD 2.31, which represents a 26 percent increase compared with the prior-year quarter. For investors, the combined picture of revenue up 18.5 percent, operating income up 31 percent and EPS up 26 percent in Q2 2026 illustrates that Intuitive Surgical is not only expanding its installed base but also converting that growth into rising profitability.

Analyst targets and valuation versus consensus

Analyst coverage remains broadly positive even after recent share price volatility. A Nasdaq quote page view cited on Yahoo Finance includes an analyst action dated September 8, 2026, where BTIG reiterated its Buy rating on Intuitive Surgical shares and maintained a price target of USD 469. This target sits well above the current price around USD 385, suggesting that BTIG sees room for further upside as the company executes on procedure growth and new indications.

Aggregated views underscore that BTIG’s stance is part of a broader positive consensus. According to MarketBeat on September 16, 2026, Intuitive Surgical currently carries a consensus rating of Moderate Buy, with an average analyst price target of about USD 508.68. A separate analysis by Deep500 notes that next-fiscal-year consensus EPS stands at USD 10.799, implying a forward price-earnings multiple of roughly 34.2 times and a PEG ratio near 1.96 based on expected growth of about 22 percent.

From a valuation perspective, this means the stock trades at a premium to the broader market but with earnings growth that helps justify that multiple for many analysts. For retail investors, the key question is whether Intuitive Surgical can sustain high-teens revenue growth and double-digit procedure expansion as competition intensifies and healthcare systems face budget constraints, because any slowdown could compress the valuation further.

Stock performance, volatility and technical context

Recent trading data show Intuitive Surgical stock recovering from a deeper drawdown earlier in 2026. As of intraday trading on September 16, 2026, Yahoo Finance quotes the shares at USD 385.99 on Nasdaq, up about 2.34 percent on the day, with the trailing one-year return at around 11.20 percent and year-to-date performance near 31.87 percent. These figures indicate that, despite bouts of volatility, the stock has delivered double-digit gains over the current year.

Broader performance snapshots highlight how the recent move fits into a longer swing. As noted in an AI-based analysis on Deep500, on September 13, 2026 Intuitive Surgical traded at USD 369.15, roughly 39 percent below its 52-week high of USD 603.88 and about 19.7 percent under its 200-day moving average. Even after the subsequent rebound to around USD 383-386, the shares still remain significantly below the 52-week high, illustrating that the market has repriced the stock downward in 2026 despite rising earnings.

This disconnect between fundamentals and share price has also been visible in recent social and analyst commentary. A sentiment roundup on Quiver Quantitative dated September 16, 2026 notes that Intuitive Surgical shares have been trading well below recent highs, with observers pointing to a double-bottom pattern that some view as a potential rebound signal. The same overview mentions that 11 analysts have issued price targets on the stock over the past six months, with a median target around USD 574, again far above the current trading level.

Risks and competitive considerations

While the CE mark approval and Q2 2026 growth figures are clear positives, several risks continue to shape the investment case. A study overview highlighted by Zacks on September 17, 2026 drew attention to clinical data showing better outcomes for da Vinci procedures across 13 common conditions, yet also noted that year to date the shares had fallen by more than 30 percent compared with a double-digit decline for the wider medical instruments industry and a gain for the S&P 500. That divergence suggests that investors have been cautious about valuation and future growth despite supportive clinical evidence.

Competitive pressures in robotic surgery and capital spending cycles at hospitals are important factors. The price decline highlighted in Quiver Quantitative has come even as quarterly earnings have risen, which Deep500 characterizes as multiple compression rather than a fundamental downturn. The analysis points out that trailing twelve-month EPS of around USD 8.854 and next-fiscal-year consensus near USD 10.799 imply that earnings are still growing, so the share-price weakness reflects investors paying a lower multiple for that growth.

For investors assessing Intuitive Surgical, the key risk is that if procedure growth or system placements were to slow below the high-teens rates seen in Q2 2026, the forward valuation of roughly 34 times earnings could come under further pressure. At the same time, new indications such as the EU expansion in gynecologic surgery and ongoing clinical data on outcomes provide tangible drivers that could help sustain growth if adoption continues.

Intuitive Surgical stock price and market metrics

Per Nasdaq-based quote data relayed on Yahoo Finance, Intuitive Surgical stock last traded at USD 385.99 on Nasdaq during intraday trading on September 16, 2026, an increase of 2.34 percent versus the prior close. The same overview lists a 52-week price range from a low near USD 324.00 to a high around USD 603.88, placing the current level roughly mid-range but still clearly below the peak. With a market capitalization reported around USD 133.52 billion in a recent note on Zacks, Intuitive Surgical remains one of the largest medical-technology companies globally, and its share price continues to be closely watched as new regulatory and clinical developments unfold.

More news and analyses on Intuitive Surgical stock